VivoSeq
Metabolic & Endocrine

Diabetes Mellitus, Type 2

19

Pipeline Programs↗

24

Active Trials↗

11

Companies Involved↗

Diabetes Mellitus, Type 2 is an emerging landscape with 19 programs across 11 companies. The most active players are Amgen, Merck & Co., Xiangbei Welman Pharmaceutical Co., Ltd. 4 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

45/100

Mech. Concentration

40/100

Completion Rate

85/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1X

Xiangbei Welman Pharmaceutical Co., Ltd

1 program

ApprovedEMD Serono logo

EMD Serono

1 program

ApprovedBoehringer Ingelheim logo

Boehringer Ingelheim

4 programs

ApprovedEli Lilly logo

Eli Lilly

5 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

12 of 14 classified programs — the dominant modality here.

14%ALL OTHERSPeptide214%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 64% of 22 pipeline programs.

Analysis

Trial Status

37

clinical trials

Completed11 · 30%
Recruiting9 · 24%
Active, not recruiting7 · 19%
Not yet recruiting6 · 16%
Withdrawn2 · 5%
Enrolling by invitation2 · 5%

Clinical Trials

Trial Activity

37 trials

A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus
Recruiting·Merck & Co. logoMerck & Co.·Phase 1·NCT07242469·52 enrolled
A Randomized Comparison of Cleerly Coronary Artery Disease Stage-Based Care Versus Risk Factor-Based Care for Primary Prevention of Cardiovascular Events
Recruiting·CCleerly, Inc.·Preclinical·NCT06112418·7,500 enrolled
EASi-PROTKT™ - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Type 2 Diabetes, Hypertension and Established Cardiovascular Disease
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT07064473·11,800 enrolled
Investigating the Efficacy of Mobile Health Monitoring and Self-care to Improve Obesity Outcomes in Hispanic Adolescence Populations
Recruiting·BBaylor College of Medicine·Preclinical·NCT06959901·30 enrolled
Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 2·NCT07415954·270 enrolled
Re-Engineered Discharge for Diabetes Care Transitions: Screening and Addressing Social Determinants of Health Needs at Hospital Discharge
Recruiting·UUniversity of Massachusetts, Worcester·Preclinical·NCT06869057·412 enrolled
The Impact of Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control
Recruiting·UUniversity of Toronto·Preclinical·NCT06118931·123 enrolled
A Phase 1 Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Recruiting·Amgen logoAmgen·Phase 1·NCT07590193·162 enrolled
A Phase 1,Double-blinded,Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of NNC1679-0001 When Administered to Healthy Participants and Participants With T2DM
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 1·NCT07570992·58 enrolled
A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 2·NCT07215312·100 enrolled
EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program
Active, not recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·N/A·NCT03363464·230,000 enrolled
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes: The PREPARED Trial
Active, not recruiting·NNorthwestern University·Preclinical·NCT04976881·840 enrolled
Strategies to Improve Well-Being and Diabetes Management
Active, not recruiting·—·Preclinical·NCT06348238·150 enrolled
Lowering Food Insecurity and Improving Diabetes With Financial Incentives (LIFT-FINANCE)
Active, not recruiting·SState University of New York at Buffalo·Preclinical·NCT05352022·150 enrolled
Food Delivery, Remote Monitoring, and Coaching-Enhanced Education for Optimized Diabetes Management (FREEDOM)
Active, not recruiting·UUniversity of Alabama at Birmingham·Preclinical·NCT05288452·304 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)